Core Insights - Brain-computer interface (BCI) technology has achieved a significant breakthrough in policy, with Shanghai Ladder Medical Technology Co., Ltd. announcing that its "implantable wireless brain-computer interface system" has entered the special review process for innovative medical devices by the National Medical Products Administration, marking a transition from laboratory to clinical application [1] - Interest in companies related to brain-computer interfaces has surged, with over ten brokerages and several investment funds conducting joint research on Xiangyu Medical [1] Company Developments - Xiangyu Medical reported a total R&D investment of 49.0947 million yuan in the third quarter, representing a year-on-year increase of 27.67%, with approximately 60%-70% allocated to brain-computer interface-related fields [2] - The company has established strategic partnerships with over 260 large hospitals to develop brain-computer interface treatment centers and research-oriented wards, aiming to cover 500 top-tier hospitals by the Spring Festival and expand to over 1,000 hospitals next year, with progress ahead of expectations [2] - Xiangyu Medical's innovative products, including those utilizing brain-computer interface technology, present new opportunities for collaboration with high-level hospitals, enhancing the company's brand positioning and influence in the high-end hospital market [2]

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-054 河南翔宇医疗设备股份有限公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 河南翔宇医疗设备股份有限公司（以下简称"公司"）第三届监事会第八次会议于2025年11月14日在公司 会议室以现场结合通讯的方式召开。会议通知于同日送达各位监事，全体监事一致同意豁免本次会议通 知时间要求。本次会议应出席监事3人，实际出席监事3人。会议由监事会主席李治锋先生主持。会议的 召开及表决程序符合有关法律、行政法规、部门规章和《公司章程》的规定。 二、监事会会议审议情况 经与会监事投票表决，本次会议审议并通过了以下议案： （一）审议通过《关于为全资子公司提供担保的议案》 经审议，监事会认为：公司本次为全资子公司提供担保，是为了满足全资子公司建设发展规划和实际生 产经营的资金需求，符合公司经营发展需要；该担保对象为公司全资子公司，担保风险可控，不会损害 公司利益；本次担保事项符合法律法规及《公司章程》的有关规定。 ...

（编辑 任世碧） 证券日报网讯 11月14日晚间，翔宇医疗发布公告称，公司于2025年11月14日召开第三届董事会第八次 会议、第三届监事会第八次会议，审议通过了《关于为全资子公司提供担保的议案》。公司全资子公司 河南瑞贝塔医疗科技有限公司（简称"瑞贝塔"）的建设发展规划和实际生产经营需要，瑞贝塔计划向金 融机构申请总额不超过人民币40，000.00万元的贷款。公司拟为瑞贝塔提供担保总额度不超过40， 000.00万元的不可撤销连带责任担保。本次担保无反担保。 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-055 河南翔宇医疗设备股份有限公司 根据河南翔宇医疗设备股份有限公司（以下简称"公司"）全资子公司河南 瑞贝塔医疗科技有限公司（以下简称"瑞贝塔"）的建设发展规划和实际生产经 营需要，瑞贝塔计划向金融机构申请总额不超过人民币 40,000.00 万元的贷款。 公司拟为瑞贝塔提供担保总额度不超过 40,000.00 万元的不可撤销连带责任担 保，具体条款届时以签订的合同为准。本次担保无反担保。 | | 被担保人名称 | | 河南瑞贝塔医疗科技有限公司 | | --- | --- | --- | --- | | | 本次担保金额 | 40,000.00 万元 | | | 担保对象 | 实际为其提供的担保余额 | 0.00 万元 | | | | 是否在前期预计额度内 | 是 □否 | ☑不适用：_________ | | | 本次担保是否有反担保 | 是 ☑否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股 | | | 子公司对 ...

河南翔宇医疗设备股份有限公司（以下简称"公司"）第三届监事会第八次 会议于 2025 年 11 月 14 日在公司会议室以现场结合通讯的方式召开。会议通知 于同日送达各位监事，全体监事一致同意豁免本次会议通知时间要求。本次会议 应出席监事 3 人，实际出席监事 3 人。会议由监事会主席李治锋先生主持。会议 的召开及表决程序符合有关法律、行政法规、部门规章和《公司章程》的规定。 二、监事会会议审议情况 经与会监事投票表决，本次会议审议并通过了以下议案： （一）审议通过《关于为全资子公司提供担保的议案》 经审议，监事会认为：公司本次为全资子公司提供担保，是为了满足全资子 公司建设发展规划和实际生产经营的资金需求，符合公司经营发展需要；该担保 对象为公司全资子公司，担保风险可控，不会损害公司利益；本次担保事项符合 法律法规及《公司章程》的有关规定。 证券代码：688626 证券简称：翔宇医疗 公告编号：2025-054 河南翔宇医疗设备股份有限公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ...

河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688626 证券简称：翔宇医疗 河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 11 月 1 河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会会议资料 河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会会议须知 河南翔宇医疗设备股份有限公司（以下简称"公司"）为维护全体股东的合 法权益，保证股东大会的正常秩序和议事效率，确保大会的顺利进行，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股东大会规则》及《公司章程》、《股 东大会议事规则》及中国证券监督管理委员会、上海证券交易所的有关规定，公 司特制定本会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务请 出席大会的股东或其代理人或其他出席者准时到达会场签到确认参会资格。会议 开始后，会议登记应当终 ...

Core Insights - The brain engineering sector is leading the market with a rise of 1.05% [1] Company Performance - Aipeng Medical saw a significant increase of 7.51% [1] - Innovation Medical experienced a rise of 4.41% [1] - Century Huatong increased by 3.41% [1] - Chengyitong, Xiangyu Medical, and Sanbo Brain Science all rose by over 2% [1]

Core Viewpoint - The company reported a slight increase in total revenue by 6.00% year-on-year, but net profit significantly decreased by 42.89% year-on-year, primarily due to increased R&D expenses of 126 million yuan, which rose by 20.15% year-on-year [2]. Group 1: Financial Performance - Total revenue increased by 6.00% year-on-year [2]. - Net profit decreased by 42.89% year-on-year [2]. - R&D expenses amounted to 126 million yuan, reflecting a year-on-year increase of 20.15% [2]. Group 2: R&D Focus - The company emphasizes research and development as a key driver for product innovation and upgrades [2]. - The strategic R&D direction focuses on applications in rehabilitation medicine, including brain-machine interfaces, exoskeleton robots, and artificial intelligence (AI) [2]. - The establishment of the Rehabilitation Robot Laboratory and Sun-BCI Lab for brain science indicates a commitment to advancing brain-machine interface technology [2]. - A significant portion of R&D investment is directed towards areas directly or indirectly related to brain-machine interface technology [2].

Core Viewpoint - The A-share market is experiencing a surge in brain-computer interface concept stocks, driven by the approval of a domestically developed implantable wireless brain-computer interface system entering the special review process by the National Medical Products Administration of China, marking a significant step in the commercialization of this technology in China [1] Group 1: Stock Performance - Aipeng Medical saw a nearly 12% increase in stock price, with a total market value of 40.03 billion and a year-to-date increase of 80.63% [2] - Century Huatong and Innovative Medical both rose over 7%, with market values of 141.1 billion and 10.5 billion respectively, and year-to-date increases of 269.65% and 198.87% [2] - Botao Biological increased by over 5%, with a market value of 6.62 billion and a year-to-date increase of 95.06% [2] - Xiangyu Medical rose over 4%, with a market value of 8.33 billion and a year-to-date increase of 78.19% [2] - Other notable stocks include Sanbo Brain Science, Saily Medical, Dineike, Taihe Technology, and Chengyi Tong, all showing increases of over 3% [1][2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive brain-computer interface product to enter the "green channel" for innovative medical devices in China, indicating a key advancement from clinical validation to market access in this cutting-edge technology field [1]

Core Viewpoint - The brain-computer interface concept stocks experienced a surge in early trading, with Aipeng Medical rising over 10%, followed by gains in Innovative Medical, Beikang, Xiangyu Medical, and Century Huato [1] Company Summary - Aipeng Medical saw a significant increase of over 10% in its stock price [1] - Innovative Medical, Beikang, Xiangyu Medical, and Century Huato also followed with upward movements in their stock prices [1]